1-(2-benzofuryl)cyclopentene | 118959-02-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并呋喃
• 英文名称: 1-(2-benzofuryl)cyclopentene
• 英文别名: 2-(cyclopent-1-en-1-yl)benzofuran；1-(2-benzofuryl)cyclopentane；2-(cyclopenten-1-yl)benzofuran；2-Cyclopenten-1-ylbenzofuran；2-(cyclopenten-1-yl)-1-benzofuran
• CAS: 118959-02-7
• 化学式: C₁₃H₁₂O
• 分子量: 184.238
• InChiKey: NQHKCIHIVKYRMZ-UHFFFAOYSA-N

物化性质

• 熔点：
  72-73 °C
• 沸点：
  292.1±19.0 °C(Predicted)
• 密度：
  1.143±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  13.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1-(2-benzofuryl)cyclopentene 在 sodium hydroxide 、 双氧水 、 乙醛 、 (-)-Monoisopinocampheylborane 作用下， 生成 (1S,2S)-(+)-2-(2-benzofuryl)cyclopentanol
  参考文献：
  名称：

  通过有机硼烷进行手性合成。11. 硼氢化。82. 1-杂芳基环烯烃与 Monoisopinocampheylborane 的不对称硼氢化反应。对映体纯度极高的反式-2-杂芳基环烷基硼酸酯和衍生醇的合成

  摘要：

  系统地研究了代表性 1-杂芳基环烯烃与单异松蒎基硼烷 (IpcBH2) 的硼氢化反应，以确定硼氢化反应过程中的不对称诱导程度。1-杂芳基环戊烯与 IpcBH2 在 -25 °C 下的硼氢化反应顺利进行，得到相应的二烷基硼烷。这些二烷基硼烷用乙醛处理然后氧化，得到相应的 85-86% ee 的反式-2-杂芳基环烷醇。类似地，1-杂芳基环己烯在用 IpcBH2 进行硼氢化反应后，再进行乙醛处理和氧化，得到相应的醇（约 10 毫升）。90% EE。衍生自 1-杂芳基环戊烯和 IpcBH2 的二烷基硼烷或烷基硼酸可以重结晶以提供接近 100% ee 的材料。从这样的二烷基硼烷或烷基硼酸，相应的硼酸盐约。制备并分离了 100% ee。这些被证明是用于有机合成的高度通用的合成中间体。

  DOI：

  10.1246/bcsj.61.93
• 作为产物：
  描述：

  1-(benzofuran-2-yl)cyclopentan-1-ol 在 对甲苯磺酸 作用下， 以 乙醚 为溶剂， 反应 0.08h， 生成 1-(2-benzofuryl)cyclopentene
  参考文献：
  名称：

  Synthesis and structure–activity relationships of novel poly(ADP-ribose) polymerase-1 inhibitors

  摘要：

  A series of novel pyrrolocarbazoles was synthesized as potential PARP-1 inhibitors. Pyrrolocarbazole 1 was identified as a potent PARP-I inhibitor (IC50 = 36 nM) from our internal database. Synthesis of analogs around this template with the aid of modeling studies led to the identification of the truncated imide 14. Compound 14 (IC50 = 40 nM), with deleted B-ring, was found to be an equipotent PARP-1 inhibitor. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.10.099

文献信息

• Novel multicyclic compounds and the use thereof
  申请人：——

  公开号：US20020028815A1

  公开（公告）日：2002-03-07

  The present invention is directed to novel multicyclic molecules that mediate enzymatic activity. In particular, the compounds may be effective in the treatment of diseases or disease states related to the activity of PARP, VEGFR2, and MLK3 enzymes, including, for example, neurodegenerative diseases, inflammation, ischemia, and cancer.

  本发明涉及介导酶活性的新型多环分子。具体而言，这些化合物可能在治疗与PARP、VEGFR2和MLK3酶活性相关的疾病或疾病状态方面具有有效性，例如神经退行性疾病、炎症、缺血和癌症。
• Suzuki-Miyaura coupling of heteroaryl boronic acids and vinyl chlorides
  作者：Ashish Thakur、Kainan Zhang、Janis Louie

  DOI：10.1039/c1cc15990a

  日期：——

  A protocol for the Suzuki-Miyaura coupling of heteroaryl boronic acids and vinyl chlorides that minimizes protodeboronation is described. A combination of catalytic amounts of Pd(OAc)(2) and SPhos in conjunction with CsF in isopropanol effectively affords a variety of coupled products. Surprisingly, a dramatic temperature dependence in product selectivity was observed.

  描述了用于杂芳基硼酸和氯乙烯的Suzuki-Miyaura偶联的方案，其使原去硼烷化最小化。异丙醇中催化量的Pd（OAc）（2）和SPhos与CsF的组合可有效提供多种偶联产物。令人惊讶地，观察到产物选择性中显着的温度依赖性。
• Multicyclic compounds and the use thereof
  申请人：Cephalon, Inc.

  公开号：US07122679B2

  公开（公告）日：2006-10-17

  The present invention is directed to novel multicyclic molecules that mediate enzymatic activity. In particular, the compounds may be effective in the treatment of diseases or disease states related to the activity of PARP, VEGFR2, and MLK3 enzymes, including, for example, neurodegenerative diseases, inflammation, ischemia, and cancer.

  本发明涉及新型多环分子，其介导酶活性。特别是，这些化合物可能在治疗与PARP、VEGFR2和MLK3酶活性相关的疾病或疾病状态方面具有有效性，包括例如神经退行性疾病、炎症、缺血和癌症。
• NOVEL MULTICYCLIC COMPOUNDS AND THE USE THEREOF
  申请人：Chatterjee Sankar

  公开号：US20110059959A1

  公开（公告）日：2011-03-10

  The present invention is directed to novel multicyclic molecules that mediate enzymatic activity. In particular, the compounds may be effective in the treatment of diseases or disease states related to the activity of PARP, VEGFR2, and MLK3 enzymes, including, for example, neurodegenerative diseases, inflammation, ischemia, and cancer.

  本发明涉及新型多环分子，可介导酶活性。特别是，这些化合物可以在治疗与PARP、VEGFR2和MLK3酶活性相关的疾病或疾病状态方面发挥作用，包括例如神经退行性疾病、炎症、缺血和癌症。
• Multicyclic compounds and their use as inhibitors of PARP, VEGFR2 and MLK3 enzymes
  申请人：CEPHALON, INC.

  公开号：EP1754707A2

  公开（公告）日：2007-02-21

  The present invention is directed to novel multicyclic molecules of formula Ia that mediate enzymatic activity. In particular, the compounds may be effective in the treatment of diseases or disease states related to the activity of PARP, VEGFR2, and MLK3 enzymes, including, for example, neurodegenerative diseases, inflammation, ischemia, and cancer.

  本发明涉及介导酶活性的式 Ia 的新型多环分子。特别是，这些化合物可有效治疗与 PARP、VEGFR2 和 MLK3 酶活性有关的疾病或疾病状态，例如包括神经退行性疾病、炎症、缺血和癌症。